sepsis. Other sepsis
Conditions
Interventions
Intervention 1: Intervention group: Patients receiving two 250 mg curcumin-phytosomal capsules (total of 500 mg daily) for 7 days (25 patients). Intervention 2: Control group: Patients receiving place
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age 18-70 years Gastrointestinal tract with normal function and intestinal nutrition criteria Diagnosis of moderate or severe trauma based on GCS index (4-15) Trauma diagnosis based on Injury Severity Score (ISS) between minor to severe
Exclusion criteria
Exclusion criteria: Impossibility of intestinal feeding in the first 48 hours of admission Any history of heart disease Patients who are expected to die within 12 hours of admission to the intensive care unit. Patients who do not have an indication for intestinal nutrition on the first day and are confirmed and predicted based on the diagnosis of the intensive care unit and will not be able to receive intestinal nutrition in the future. (Nausea, persistent vomiting, ileus, intestinal obstruction, uncontrolled diarrhea (> 500 ml / day), high-output fistula (> 500 ml / day), intestinal inaccessibility, incomplete resuscitation and hemodynamic instability Patients with BMI <18.5kg / m2 admitted to the intensive care unit. Patients who receive nutritional support through complete intravenous feeding Patients with a history of underlying disease such as diabetes, congenital and immune disorders, renal and hepatic insufficiency, and pancreatitis. Taking anticoagulants such as heparin, warfarin, aspirin, etc. The unwillingness of the patient or his legal guardian to participate in the project Patients who are hospitalized in the intensive care unit for less than 48 hours Pregnancy and lactation Severe septic shock or sepsis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammation. Timepoint: Before and after the intervention. Method of measurement: Measurement of inflammatory markers by serum.;Mortality 28 days. Timepoint: Before and after the intervention. Method of measurement: Use existing statistics.;Duration of hospitalization. Timepoint: Before and after the intervention. Method of measurement: Use of questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the number of blood cells. Timepoint: Before and after the intervention. Method of measurement: Blood cell count test.;Blood sugar changes. Timepoint: Before and after the intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;Serum total protein. Timepoint: Before and after the intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;BUN. Timepoint: Before and after the intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;Liver enzymes. Timepoint: Before and after the intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;Lactate Dehydrogenase (LDH). Timepoint: Before and after the intervention. Method of measurement: ELISA method.;Serum albumin. Timepoint: Before and after the intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;Serum creatinine. Timepoint: Before and after the intervention. Method of measurement: Biochemical test by enzymatic method by Hitachi 902 device.;NUTRIC score. Timepoint: Before and after the intervention. Method of measurement: By scoring a questionnaire including APACHE II and SOFA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Bagherniya
Esfahan University of Medical Sciences
Outcome results
None listed